SCHEMBL6475845

SCHEMBL6475845

CCCS(=O)(=O)NCc1ccc(-c2ccc(OC(C)CNS(=O)(=O)CCC)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 1/20 0.41
TP53 P04637 2/20 0.39
ACACB O00763 2/20 0.39
JAK1 P23458 1/20 0.38
JAK2 O60674 1/20 0.38
FLT3 P36888 1/20 0.38
HTT P42858 2/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
ACACA Q13085 1/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6766022 0.96 TP53 (0.41) GRIA4TP53ACACBJAK1JAK2
SCHEMBL6480391 0.94 TP53 (0.40) GRIA4TP53ACACBJAK1JAK2
SCHEMBL6482324 0.92 GRIA4 (0.46) GRIA4TP53ACACBTSHRMTNR1A
SCHEMBL6475840 0.90 CA2 (0.41) GRIA4TP53ACACBJAK1JAK2
SCHEMBL6481142 0.88 MTNR1A (0.47) ACACBMTNR1AMTNR1BACACAALDH1A1
Hydrochloric Acid SCHEMBL6475280 0.88 GRIA4 (0.40) GRIA4TP53ACACBMTNR1AMTNR1B
SCHEMBL6473902 0.88 GRIA4 (0.41) GRIA4TP53ACACBHTTLMNA
SCHEMBL6475448 0.87 ERCC1 (0.39) GRIA4MTNR1AMTNR1BCA1CA2
SCHEMBL6475297 0.87 GRIA4 (0.48) GRIA4HTTSMN1; SMN2MTNR1AMTNR1B
SCHEMBL6482161 0.87 MTNR1A (0.49) GRIA4TP53TSHRMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 GRIA4 6/4885TP53 4836/4885ACACB 4506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.